v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities    
Net loss $ (41,243) $ (16,772)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization expense 1,321 3
Stock-based compensation - Lucid Diagnostics Inc. 10,371 6,045
Stock-based compensation - PAVmed Inc. 880 111
APA-RDx: Issue common stock - settle installment payment 427
Changes in operating assets and liabilities:    
Accounts receivable 169 (200)
Prepaid expenses and other current assets 171 (954)
Accounts payable (388) 781
Accrued expenses and other current liabilities 16 136
Accrued CWRU License Agreement Fee (223)
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee 2,849 2,688
Due To: PAVmed Inc. - Interest Expense - Senior Unsecured Promissory Note 594
Net cash flows used in operating activities (25,427) (7,791)
Cash flows from investing activities    
Purchase of equipment (705) (38)
Payments - Acquisition (3,200)
Net cash flows used in investing activities (3,905) (38)
Cash flows from financing activities    
Proceeds – issue of common stock – Committed Equity Facility 1,807
Proceeds – exercise of stock options 694
Proceeds – issue common stock – Employee Stock Purchase Plan 109
Proceeds – Due To: PAVmed Inc. - working capital cash advances 7,739
Net cash flows provided by financing activities 2,610 7,739
Net increase (decrease) in cash (26,722) (90)
Cash, beginning of period 53,656 111
Cash, end of period $ 26,934 $ 21

Source